Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.34 |
| ▸ | CTSD | P07339 | 1/20 | 0.34 |
| ▸ | CTSE | P14091 | 1/20 | 0.34 |
| ▸ | BACE1 | P56817 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2349037 | 1.00 | CCR5 (0.47) | CCR5CYP2D6CYP1A2PKMSMN1; SMN2 | |
| SCHEMBL7627455 | 0.84 | CYP1A2 (0.39) | CCR5CYP2D6CYP1A2PKMSMN1; SMN2 | |
| SCHEMBL1546590 | 0.83 | CYP1A2 (0.38) | CCR5CYP2D6CYP1A2PKMSMN1; SMN2 | |
| SCHEMBL12406856 | 0.83 | CYP1A2 (0.38) | CCR5CYP2D6CYP1A2PKMSMN1; SMN2 | |
| SCHEMBL12530161 | 0.83 | CCR5 (0.45) | CCR5CYP2D6CYP1A2PKMSMN1; SMN2 | |
| SCHEMBL12283380 | 0.83 | CCR5 (0.45) | CCR5CYP2D6CYP1A2PKMSMN1; SMN2 | |
| SCHEMBL9481133 | 0.81 | NR1I2 (0.47) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL7516303 | 0.81 | CA12 (0.46) | CYP2D6CYP1A2PKMSMN1; SMN2NPSR1 | |
| SCHEMBL7255639 | 0.78 | TAAR1 (0.45) | TAAR1 | |
| SCHEMBL7259968 | 0.78 | TAAR1 (0.45) | TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9340517-B2 | Methods of modulating the activity of the MC5 receptor and treatment of conditions related to this receptor | MIMETICA PTY LTD (AU) | 2016-05-17 | — | — | US | disclosed |
| US-20140128380-A1 | METHODS OF MODULATING THE ACTIVITY OF THE MC1 RECEPTOR AND TREATMENT OF CONDITIONS RELATED TO THIS RECEPTOR | MIMETICA PTY LTD (AU) | 2014-05-08 | — | — | US | disclosed |
| US-20130225563-A1 | METHODS OF MODULATING THE ACTIVITY OF THE MC5 RECEPTOR AND TREATMENT OF CONDITIONS RELATED TO THIS RECEPTOR | MIMETICA PTY LTD (AU) | 2013-08-29 | — | — | US | disclosed |
| US-8440653-B2 | 3-substituted-1,4-diazepan-2-one melanocortin-5 receptor antagonists | MIMETICA PTY LTD (AU) | 2013-05-14 | — | — | US | disclosed |
| US-8343958-B2 | 3-aminoalkyl-1,4-diazepan-2-one melanocortin-5-receptor antagonists | MIMETICA PTY LTD (AU) | 2013-01-01 | — | — | US | disclosed |
| US-20110263572-A1 | 3-AMINOALKYL-1,4-DIAZEPAN-2-ONE MELANOCORTIN-5-RECEPTOR ANTAGONISTS | MIMETICA PTY LTD (AU) | 2011-10-27 | — | — | US | disclosed |
| US-20110059952-A1 | 3-SUBSTITUTED-1,4-DIAZEPAN-2-ONE MELANOCORTIN-5 RECEPTOR ANTAGONISTS | MIMETICA PTY LTD (AU) | 2011-03-10 | — | — | US | disclosed |
| US-4920221-A | CENTRAL NERVOUS SYSTEM ACTIVE AGENTS | PFIZER INC. (US) | 1990-04-24 | — | — | US | disclosed |
| US-4642373-A | Substituted dodecahydrotripheylenes, and decahydropyrrolo[1,2-f]phenanthridines as CNS agents | PFIZER INC. (US) | 1987-02-10 | — | — | US | disclosed |
| US-4476131-A | ANTIEMETICS, ANALGESICS | PFIZER INC. (US) | 1984-10-09 | — | — | US | disclosed |
| US-4473704-A | ANALGESICS, ANTIEMETICS | PFIZER INC. (US) | 1984-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263572-A1 | 3-AMINOALKYL-1,4-DIAZEPAN-2-ONE MELANOCORTIN-5-RECEPTOR ANTAGONISTS | MC5R, MC1R, MC3R | CCR5 107/4885CYP2D6 2091/4885CYP1A2 1644/4885 |
| US-20140128380-A1 | METHODS OF MODULATING THE ACTIVITY OF THE MC1 RECEPTOR AND TREATMENT OF CONDITIONS RELATED TO THIS RECEPTOR | MC1R, MC5R, MC3R | CCR5 1069/4885CYP2D6 3002/4885CYP1A2 1547/4885 |
| US-20130225563-A1 | METHODS OF MODULATING THE ACTIVITY OF THE MC5 RECEPTOR AND TREATMENT OF CONDITIONS RELATED TO THIS RECEPTOR | MC5R, MC1R, MC3R | CCR5 182/4885CYP2D6 2000/4885CYP1A2 1420/4885 |
| US-20110059952-A1 | 3-SUBSTITUTED-1,4-DIAZEPAN-2-ONE MELANOCORTIN-5 RECEPTOR ANTAGONISTS | MC5R, MC1R, MC3R | CCR5 89/4885CYP2D6 1331/4885CYP1A2 1021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.